Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10556185 | PMC |
| http://dx.doi.org/10.1016/j.ymthe.2023.07.023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An Open-Label Phase II Trial of Pembrolizumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Azacitidine as Second-Line Therapy for Advanced Head and Neck Squamous Cell Cancers.
Health Sci Rep
January 2025
Medical Oncology Healthcare Global Bangalore India.
Background And Aims: Sensitivity to immune checkpoint inhibitor (ICI) therapy depends in part on the genetic and epigenetic makeup of cancer cells, and CD8 T-lymphocytes that mediate immune responses. Epigenetics are heritable reversible changes in gene expression that occur without any changes in the nuclear DNA sequence or DNA copy number.
Primary Objective: i.
Circulating tumor DNA in head and neck squamous cell carcinoma-current status and future prospects.
Acad Oncol
December 2024
Department of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago, IL 60637, USA.
Squamous cell carcinoma (SCC) is the most common malignancy of the head and neck. Stagnating survival rates in recent decades, despite advances in the treatment paradigms, surveillance technologies, and multidisciplinary care, leave clinicians with a need for better options for screening, risk-stratifying, and monitoring patients. A growing proportion of patients with HPV-associated SCC have improved outcomes but continue to have a heterogenous response to treatment.
View Article and Find Full Text PDFDurable Complete Remission of Metastatic Gastric Cancer Following Platinum-Based Chemotherapy: A Case Report.
Cureus
December 2024
Oncology Department, Faculty of Medicine, Jagiellonian University Medical College, Cracow, POL.
Gastric cancer is a common type of gastrointestinal tract malignancy. It is characterized by a poor prognosis - median survival for metastatic disease is about 12 months. A small percentage of gastric cancer is characterized by high sensitivity to systemic treatment, resulting in deep and durable responses.
View Article and Find Full Text PDFAt the nucleus of cancer: how the nuclear envelope controls tumor progression.
MedComm (2020)
February 2025
Historically considered downstream effects of tumorigenesis-arising from changes in DNA content or chromatin organization-nuclear alterations have long been seen as mere prognostic markers within a genome-centric model of cancer. However, recent findings have placed the nuclear envelope (NE) at the forefront of tumor progression, highlighting its active role in mediating cellular responses to mechanical forces. Despite significant progress, the precise interplay between NE components and cancer progression remains under debate.
View Article and Find Full Text PDFInsights on Bmi-1 therapeutic targeting in head and neck cancers.
Oncol Res
January 2025
LICIFO, Department of Restorative Sciences, Faculty of Dentistry, University of Costa Rica (HNSCC), San José, 11501, Costa Rica.
The B lymphoma Mo-MLV insertion region 1 homolog (Bmi-1) protein of the polycomb complex is an essential mediator of the epigenetic transcriptional silencing by the chromatin structure. It has been reported to be crucial for homeostasis of the stem cells and tumorigenesis. Though years of investigation have clarified Bmi-1's transcriptional regulation, post-translational modifications, and functions in controlling cellular bioenergetics, pathologies, and DNA damage response, the full potential of this protein with so many diverse roles are still unfulfilled.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!